Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Global cues lift Indian markets
Mon, 24 Oct 09:30 am

Asian stock markets have opened the day on a positive note. Stock market in Hong Kong (up 3.8%), South Korea (up 2.6%) and Indonesia (up 2%) are leading the gains. The Indian stock markets have also opened the day on a firm note. Stocks in the metal, auto and banking space are leading the gains.

The BSE-Sensex is trading higher by 284 points (1.7%) and the NSE-Nifty is up by around 86 points (1.7%). BSE Midcap and BSE Small cap stocks are trading in the green as well, with the BSE Mid Cap and BSE Small Cap indices up by 1% and 0.8% respectively. The rupee is trading at 49.80 to the US dollar.

Pharma Stocks have opened the day on a firm note with Ranbaxy Laboratories and Cipla in the green. Piramal Healthcare Limited (PHL) announced its second quarter results for the financial year 2011-2012 (2QFY12). For the continuing businesses, income was up by 32% YoY to Rs 5,347 m. The operating profit for the quarter was at Rs 1,298 m against an operating loss of Rs 386 m in 2QFY11. The operating profit margin for the quarter was higher at 24.3%. Net profit for the quarter was Rs 524 m. Pharma Solutions (CRAMS) business recorded sales of about Rs 3 bn during 2QFY12 against Rs 2.3 bn in 2QFY11, registering growth of 32.4% YoY. The revenues from the Indian facilities grew by 82.7% YoY to Rs 1.9 bn. The management is expecting a strong growth in the commercial manufacturing assets in India driven by increased sales. The company also stated that the de-merger process of R&D (research & development) unit of Piramal Life Sciences Ltd into PHL has commenced.

Cement stocks have opened the day on a firm note with Ambuja Cements, Associated Cement Companies Limited (ACC Ltd) and UltraTech Cement leading the gains. UltraTech Cement recently announced its financial results for the quarter ended September 2011. During the quarter, the company reported a rise of 22% YoY and 141% YoY in sales and net profits respectively. The seemingly improved performance was mainly on account of a lower base effect. In fact, the company's performance was subdued if compared with that of the quarter ended June 2011. Sluggish demand, weak realisations and significant increase in costs were the main reasons for it. The company's operating margins improved from 12.7% in 2QFY11 to 14.9% in 2QFY12. Higher other income, lower interest charges boosted the company's bottomline which surged by 141% YoY. Net margins improved from 3.6% in 2QFY11 to 7.1% in 2QFY12.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Global cues lift Indian markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.